Additional Resources
These materials provide additional background on the problem of cancer drug overdosing, and highlight OCCA’s ongoing work in this space.
Government Action:
OCCA Submissions:
Videos:
- Optimal Cancer Care Alliance Virtual Meeting (2022)
- First International Summit on Interventional Pharmacoeconomics (2020)
- ASCO Recap (2021) – Video Excerpt
News Coverage, Op-Eds, and Blog Posts
- FDA commissioner, two senators raise concerns about patent abuse (2021)
- RIP MTD (Maximum Tolerated Dose): FDA to require sponsors to determine optimal dosage (2021)
- Optimize the dose: An optimal step forward for FDA (2021)
- FDA’s ‘Project Optimus’ Will Encourage Move Away From Conventional Dose-Finding (2021)
- Empowering the FDA to Require Dose Optimization (2021)
- Study identifies targeted therapy’s cardiac risks (2019)
- Funding Interventional Pharmacoeconomic Studies: A New Paradigm (2019)
- The Potential of Value-Based Prescribing in Oncology (2019)
- Archived News Coverage Op-Eds
Medical and Scientific Journal Articles
- Oncology Drug Prescribing: Greed and Fear (2022) *
- Dosing Ibrutinib: Eliminating the Use of Brute Force (2022) *
- When Less May Be Enough (2022)
- Improving access to immunotherapy in low- and middle-income countries (2022) *
- Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan (2022) *
- Lorlatinib Exposed: A Far From Optimal Dose (2022) *
- Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings (2022) *
- Subcutaneous Atezolizumab: A Jab Without a Benefit (2021) *
- Combination therapy patents: a new front in evergreening (2021) *
- Dose Optimization of Pembrolizumab: Less May Be More (2021) *
- Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message? (2021) *
- A Pharmacokinetic Simulation Analysis of Less Frequent Dosing: Pharmacoeconomic Rationale for Dose De-Escalation (2021) *
- Negative Innovation: When Patents are Bad For Patients (2021) *
- Near- Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments (2021) *
- The Abiraterone Dosing Chess Match (2021) *
- Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets (2020) *
- Interventional Pharmacoeconomics : A Novel Mechanism for Unlocking Value (2020) *
- Potential Cost Savings With Low-Dose Abiraterone in the United States (2020)
- Archived Journal Articles
* = article written or co-authored by a member of the Optimal Cancer Care Board of Directors